Aurora Cannabis (ACB) vs Eton Pharmaceuticals (ETON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Aurora Cannabis (ACB) over the past year, gaining 161.6% versus a loss of 27.4%. Over five years, ETON leads with a +950.9% price change compared with -93.7% for ACB. Eton Pharmaceuticals is the larger company by market cap ($1.56 billion vs $280.5 million), about 5.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACB | ETON |
|---|---|---|
| Share price | $4.43 | $54.75 |
| Market cap | $280.46M | $1.56B |
| 1-day change | -0.67% | -0.24% |
| YTD return | +4.98% | +223.77% |
| 1-year return | -27.38% | +161.59% |
| 5-year return | -93.70% | +950.86% |
| P/E ratio (TTM) | — | 136.88 |
| Forward P/E | — | 21.22 |
| EPS (TTM) | $-0.61 | $0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $79.95M |
| Revenue growth (YoY) | — | +104.94% |
| Net income (latest FY) | — | $-4.60M |
| Gross margin | — | 53.46% |
| Operating margin | — | -1.06% |
| Net margin | — | -5.75% |
| 52-week high | $6.67 | $66.37 |
| 52-week low | $2.56 | $14.27 |
| Distance from 52-week high | -33.53% | -17.51% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | — | +29.68% |
| Average volume | 1.36M | 609.36K |
| Shares outstanding | 63.31M | 28.58M |
| Employees | 1,028 | 44 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Eton Pharmaceuticals is about 5.6 times larger than Aurora Cannabis by market value ($1.56B vs $280.46M).
- ETON has outperformed ACB by 189.0 percentage points over the past year.
About Aurora Cannabis
ACB stock →Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,028 employees
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Healthcare · Drug Manufacturers - Specialty & Generic · 44 employees
ACB vs ETON FAQ
Which is bigger, Aurora Cannabis or Eton Pharmaceuticals?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.56B compared with $280.46M for Aurora Cannabis (ACB).
Which stock has performed better over the past year, ACB or ETON?
ETON returned +161.59% over the past 12 months, compared with -27.38% for ACB (price return, excluding dividends). Past performance does not predict future results.
Are Aurora Cannabis and Eton Pharmaceuticals in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.